{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:37:26Z","timestamp":1783039046793,"version":"3.54.6"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>The current analysis is a part of an ongoing observational study that began in February 2021 in the Sir Sunder Lal Hospital (Varanasi, Uttar Pradesh) in northern India and is expected to continue until June 2022. This analysis aimed to delineate the clinical presentation and risk factors of occurrence and severity of COVID-19 in vaccinated individuals. The study enrolled health-care workers and the elderly receiving the COVID-19 vaccine at one of three centers linked to the study hospital. The participants received the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine based on the chimpanzee adenovirus platform (manufactured in India by the Serum Institute of India). The adenovirus codes for the spike (S) protein of SARS-CoV-2. Participants were contacted by phone at pre-decided intervals and questioned about the occurrence of COVID-19, clinical presentation, severity, and persistence of symptoms. A logistic regression analysis was performed to predict the risk factors of occurrence and severity of COVID-19. Of the 1,500 participants included in the analysis, 418 developed COVID-19 (27.9%). Fever was the most common symptom (72%), followed by cough (34%) and rhinitis (26%). Cardiovascular involvement was seen in more than 2% of individuals, and 11% had post-COVID-19 complaints. Regression analysis showed 1.6 times greater odds of contracting the disease in females and in those younger than 40 years, 1.4 times greater odds in individuals who were overweight, and 2.9 times greater odds in those receiving only one dose, compared with respective comparators. Individuals receiving two doses at a gap of \u2264 30 days had 6.7 times greater odds of infection than those receiving at a &gt; 60-day interval. There was no association between COVID-19 occurrence in the vaccinees and pre-vaccination history of SARS-CoV-2 infection. Males were at a 3.6 times greater risk, and persons with preexisting lung disease\u2014mainly asthma\u2014had a 5.9 times greater risk of experiencing moderate to severe COVID-19 than comparators. While an extended interval between the two vaccine doses seems to be a better strategy, gender differences and an association of asthma phenotypes with COVID-19 need to be explored.<\/jats:p>","DOI":"10.4269\/ajtmh.22-0172","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:08:52Z","timestamp":1659960532000},"page":"850-855","source":"Crossref","is-referenced-by-count":3,"title":["Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19\u2013Vaccinated Priority Groups"],"prefix":"10.4269","volume":"107","author":[{"given":"Upinder","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Bala","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisweswar","family":"Ojha","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhairav Kumar","family":"Pathak","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Joshi","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Kumar","family":"Yadav","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Kansal","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankha Shubhra","family":"Chakrabarti","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Clin Immunol","doi-asserted-by":"publisher","first-page":"108427","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: a review","volume":"215","year":"2020"},{"key":"b2","year":"2022"},{"key":"b3","series-title":"Lancet Infect Dis","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1473-3099(21)00567-3","article-title":"India\u2019s COVID-19 vaccination drive: key challenges and resolutions","volume":"21","year":"2021"},{"key":"b4","series-title":"EClinicalMedicine","doi-asserted-by":"publisher","first-page":"101038","DOI":"10.1016\/j.eclinm.2021.101038","article-title":"A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers: first results from India","volume":"38","year":"2021"},{"key":"b5","series-title":"Eur J Intern Med","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejim.2021.08.005","article-title":"ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections","volume":"93","year":"2021"},{"key":"b6","series-title":"Mayo Clin Proc","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.mayocp.2021.06.003","article-title":"Protective effect of COVID-19 vaccine among health care workers during the second wave of the pandemic in India","volume":"96","year":"2021"},{"key":"b7","series-title":"J Med Virol","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/jmv.27320","article-title":"Occurrence of COVID\u201019 in priority groups receiving ChAdOx1 nCoV\u201019 coronavirus vaccine (recombinant): a preliminary analysis from north India","volume":"94","year":"2022"},{"key":"b8","series-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","year":"2020"},{"key":"b9","series-title":"Metabolism","doi-asserted-by":"publisher","first-page":"154262","DOI":"10.1016\/j.metabol.2020.154262","article-title":"Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York","volume":"108","year":"2020"},{"key":"b10","series-title":"J Ovarian Res","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13048-020-00734-4","article-title":"Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age","volume":"13","year":"2020"},{"key":"b11","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e0253193","DOI":"10.1371\/journal.pone.0253193","article-title":"Sex differences in the incidence, mortality, and fatality of COVID-19 in Peru","volume":"16","year":"2021"},{"key":"b12","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","year":"2021"},{"key":"b13","series-title":"Ther Adv Drug Saf","first-page":"20420986211011345","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis","volume":"12","year":"2021"},{"key":"b14","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1093\/cid\/ciaa1592","article-title":"The effect of prior angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment on coronavirus disease 2019 (COVID-19) susceptibility and outcome: a systematic review and meta-analysis","volume":"72","year":"2021"},{"key":"b15","series-title":"Sci Rep","doi-asserted-by":"publisher","first-page":"11130","DOI":"10.1038\/s41598-021-90491-1","article-title":"Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes","volume":"11","year":"2021"},{"key":"b16","series-title":"Front Immunol","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3389\/fimmu.2020.01184","article-title":"Influence of androgens on immunity to self and foreign: effects on immunity and cancer","volume":"11","year":"2020"},{"key":"b17","series-title":"ERJ Open Res","first-page":"00216","article-title":"Is asthma a risk factor for COVID-19? Are phenotypes important?","volume":"7","year":"2021"},{"key":"b18","series-title":"Lancet Respir Med","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-2600(21)00007-2","article-title":"Are women with asthma at increased risk for severe COVID-19?","volume":"9","year":"2021"},{"key":"b19","series-title":"Viruses","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/v14040802","article-title":"Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium","volume":"14","year":"2022"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/4\/article-p850.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/4\/article-p850.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/107\/4\/article-p850.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T16:08:38Z","timestamp":1665590918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/107\/4\/article-p850.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":19,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.22-0172","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}